SMO and medulloblastoma: The search for small molecules that might act upstream of the GPR56‐associated network led us to the CDK7/12/13 inhibitor THZ1, as it had been shown to overcome resistance to SMO antagonists in medulloblastoma by acting upstream and independent of SMO (Liu et al, 2019).